Tymlos
(Abaloparatide)ApprovedPeptide
This medication is a synthetic hormone injection used to treat osteoporosis in postmenopausal women and men at high risk of bone fractures. It works by stimulating the body to build new bone tissue and increase bone strength and density.[2] Tymlos is currently approved and in use across 4 indications[4].[1]
Tymlos is one of 63 small molecule programs targeting Total Knee Arthroplasty. It is currently in Approved.
4
Indications
13
Total Trials
4
Active Trials
62
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
9
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
66 competitors in Total Knee Arthroplasty
#DrugCompanyPhaseTrials
1Cyklokapron
JJ Molner
Approved
Naropin
FFresenius Kabi USA, LLC
Approved
Marcaine
IInnocoll
Approved
Decadron
AAspen Global Incorporated
Approved
Medrol
PfizerApproved
Journavx
Vertex PharmaceuticalsApproved
Lexapro
AbbVieApproved
Duragesic
CCephalon
Approved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Osteoporosis2 trials
7 more indications
Postmenopausal Women1 trial
Myelodysplastic Syndromes1 trial
Spinal Fusion1 trial
Lumbar Degenerative Disease1 trial
Osteoporosis, Postmenopausal1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Apr 28, 2017
TYMLOS
NDA NDA208743
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Tymlos drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Abaloparatide. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]FDA Orange Book — Patent and exclusivity data for Tymlos. U.S. Food & Drug Administration.
- [7]
Details
Drug Info
Quick Facts
- Modality
- Peptide[3]
- Highest Phase
- Approved[1]
- Company
- RRadius Health, Inc.